HT
Hisamitsu Pharmaceutical Co., Inc.
HTSUY · OTC
$2.94 +0.00% (+$0.00)
Market Cap $2.64B
P/E Ratio 20.93x
Div. Yield -
ROE 7.03%
Bulios Fair Price
$3.17
7.8% upside
Current Price
$2.94
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HTSUY is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
55 /100
Fair P/E 20.93x
P/B 1.41x
EV/EBITDA 11.76x
Growth
74 /100
Growing EPS growth 5.83%
Book val. growth 9.25%
Rev. growth 408.04%
Profitability
61 /100
Moderate Gross margin 58.96%
FCF margin 5.82%
Net margin 11.75%
Quality
33 /100
Poor ROIC 4.85%
Asset turnover 0.46x
ROE 7.03%
Debt
100 /100
Low Debt/Equity 0.01x
Net debt/EBITDA -4.09x
Current ratio 4.08x
Stability
45 /100
Moderate Beta 0.04x
Profitable years 6
Rev. volatility 6,812.59%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HTSUY
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Kazuhide Nakatomi
Employees
2,769
Headquarters
Tosu